If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
196
results.
Updated on
14/09/2026 [07:59:00]
Results 125 to 150 of 196
Absstract of: US20260224136A1
0000 An example continuous glucose monitor includes a printed circuit board (“PCB”) having first and second outer layers and an inner layer; a semiconductor package having a plurality of pins coupled to the first outer layer of the PCB; an electrical contact formed on the second outer layer of the PCB; a trace having a first portion disposed on the first outer layer, a second portion disposed on the inner layer, and a third portion disposed on the second outer layer, the trace having a first end coupled to a first pin of the plurality of pins and a second end coupled to the electrical contact; and an encapsulant disposed around a perimeter of the semiconductor package, the encapsulant covering the plurality of pins, the first portion of the sensor trace, the third portion of the sensor trace, wherein an upper surface of the semiconductor package remains exposed.
Absstract of: US20260224809A1
0000 In accordance with one aspect, a medication infusion device is provided that includes a patch pump configured to be removably adhered to a wearer's skin for delivering doses of medication (e.g., insulin) from a cartridge (e.g., a pre-filled cartridge) through a transcutaneous portion. The medication infusion system may include a pumping system configured to advance a plunger in the cartridge to cause medication in the cartridge to be delivered to the patient. The pumping mechanism may be an improved system that reduced errors in medication administration.
Absstract of: WO2026161967A1
A pharmaceutical composition co-formulating insulin and C-peptide for simultaneous delivery to restore physiological coordination is described. The invention is based on the discovery, validated by advanced artificial intelligence (AI) modeling, that C-peptide acts on at least three distinct receptors (the Insulin Receptor, GPR146, and RXFP1) to potentiate insulin signaling, terminate pro-metabolic signals that lead to hypercortisolemia and dyslipidemia, and activate anti-fibrotic pathways. This approach is supported by a model of an integrated hormonal network where the relaxin, C-peptide, and cortisol systems are interwoven through central neuroendocrine modulation, direct molecular crosstalk, and metabolic convergence. These coordinated mechanisms provide comprehensive diabetes management beyond glucose control. The co-formulation is approximately 7-fold more mass-efficient than insulin monotherapy. Furthermore, the invention provides a dual-mechanism neuroprotective therapy for Alzheimer's disease by inhibiting amyloid-beta production in neurons and promoting its clearance by microglia via a novel neuro-immune pathway.
Absstract of: AU2026206162A1
A glucose monitoring system, comprising: a glucose sensor comprising a portion configured to be positioned in a body of a user in fluid contact with a bodily fluid to sense glucose in the bodily fluid; and sensor electronics coupled to the glucose sensor, the sensor electronics comprising: one or more processors, memory coupled with the one or more processors, and wireless communication circuitry configured to communicate data indicative of glucose levels based on the sensed glucose in the bodily fluid according to a Bluetooth communication protocol; and a reader device comprising: a display; one or more processors; a transceiver configured to receive the data indicative of the glucose levels; a memory coupled to the one or more processors of the reader device and storing instructions that when executed by the one or more processors of the reader device cause the one or more processors of the reader device to: determine a glucose curve based on the data indicative of the glucose levels, wherein the glucose curve is associated with a glucose response to an event, calculate a numerical score for the event, wherein the numerical score is based in part on an area under the glucose curve and a duration of the glucose response to the event, determine a cumulative score comprising a sum of the numerical scores associated with a plurality of events, and output on the display the cumulative score and a target score. ul u l
Absstract of: AU2025207075A1
The present disclosure provides cells that are competitive with respect to cancer cells, without experiencing starvation or exhaustion, even in glucose-depleted environments. Specifically, the present disclosure provides survivor T cells with enhanced glucose uptake capacity. The T cells are modified so as to express a glucose transporter and/or configured such that the expression of a glucose transporter is enhanced. Also provided are a cell population including such cells, a pharmaceutical composition, and a treatment method.
Absstract of: WO2026164338A1
Provided are a method and an electronic device, the method comprising: acquiring blood glucose information of a user from a continuous blood glucose monitoring device; displaying a user interface including a plurality of objects; changing a specific time indicated by an indicator in response to user interaction with the indicator; and displaying a fifth object for inputting an event in response to user interaction with an input component.
Absstract of: US20260224480A1
A system for oral delivery of an active ingredient is provided, the system including: a mucoadhesive layer including a mucoadhesive and an active ingredient; and a backing layer extending over the mucoadhesive layer, the backing layer including a bulk agent, the active ingredient being selected from the group consisting of nicotine, caffeine, anatabine, at least one cannabinoid such as tetrahydrocannabinol, and a combination thereof, the system being orally dissolvable, and the bulk agent being selected from the group consisting of at least one mono-, di-, and/or polysaccharide, at least one sugar alcohol, and a combination thereof.
Absstract of: WO2026164339A1
A method and an electronic device are provided, the method comprising: acquiring blood glucose information of a user from a continuous blood glucose monitoring device; displaying a user interface including a plurality of objects; changing a specific time indicated by an indicator in response to user interaction with the indicator; displaying a fifth object for inputting an event in response to user interaction with an input component; and storing or transmitting to an external electronic device at least one of a first object, a second object, and a third object in response to user interaction with a fourth object.
Absstract of: US20260226424A1
0000 The present invention provides a method for washing lymphocytes, including washing lymphocytes with a bicarbonate ion-containing physiological aqueous solution; a method for cryopreserving lymphocytes, including suspending and freezing lymphocytes obtained by the method in a cryopreservation solution containing a physiological aqueous solution; a washing solution for lymphocytes, including a bicarbonate ion-containing physiological aqueous solution; a cryopreservation solution for lymphocytes, containing a bicarbonate ion-containing physiological aqueous solution, dextran, glucose, DMSO, and human serum albumin; a lymphocyte-containing composition, containing lymphocytes treated with a bicarbonate ion-containing physiological aqueous solution and the aforementioned cryopreservation solution; a kit for preparing lymphocytes for transplantation, containing the lymphocyte-containing composition and a diluent for transplantation containing a bicarbonate ion-containing physiological aqueous solution, and the like.
Absstract of: US2025099674A1
Disclosed herein are systems and methods for transitioning between different CGM sensors in an infusion pump system with no loss in continuity of glucose levels between different sensor for use in closed loop diabetes therapy. Notifications can be provided to the user when a subsequent CGM sensor ought to be inserted, based on specific mechanics of the previous CGM sensor and of the anticipated subsequent CGM sensor. The system can further provide a notification when the subsequent CGM sensor is activated following the warm up period and capable of transmitting CGM data for use in the system and can prompt the user to or automatically transition the system from communicating with the previous sensor for CGM data to the subsequent sensor. Following the transition, the system may also notify the user that the previous CGM sensor can be removed from the user's body.
Absstract of: GB2703647A
A system capable of tracking medicine comprising a locating device attached to the item to be tracked such as an insulin pen. The system may also comprise a smart phone app for connecting with the locating device and receiving the location information, a purpose built plastic container that holds the tracking components and attaches to the device to be tracked, and a light or a means of making sound within the tracking device to alert a user to the location of the item. Figure 1
Absstract of: US2025108160A1
0000 Systems and methods are provided for managing communication with a user of an insulin pump system for improving insulin pump operation and/or a user experience relating to the insulin delivery system. The insulin pump system may analyze data from a user of a certain insulin pump and/or data from users of different insulin pumps and determine patterns relating to such use and indicative of certain user experiences. Based on the detected patterns and/or events associated with the patterns or user experiences, user messages may be proactively sent a user device and/or smart device of the user. The user messages may be designed to improve a user experience and/or prevent a negative outcome. For example, a message may be a training video, may include a reminder to adjust pump operation for a certain activity, and/or may include an alert to reorder more supplies.
Absstract of: US2025111918A1
0000 Systems and methods are provided including insulin pump systems for determining certain information about a user of a wearable insulin pump based on naturally spoken user data by applying the user data to a large language model (LLM) or other machine learning model to parse the user data into categories. For example, certain rules and/or constraints may be provided to the LLM and may cause the LLM or machine learning model to parse the user data into defined categories that may be used for updating a user record. Categories may include food consumption, activities, sleep, and/or pump operation information, for example. Additional data may be determined from the parsed data such as caloric information, exercise duration, sleep information and the like. The parsed categorized data and/or additional data may be used to adjust operation of the insulin delivery pump.
Absstract of: EP4529835A1
0001 A method of non-invasive determination of the blood glucose concentration in the patient's tissue based on a radio noise signal received using an antenna brought close to the patient's skin according to the invention is distinguished by that the radio noise signal is received using a total power radiometer and additionally the method includes the following steps: a step of obtaining transformation coefficients, a step of measuring the temperature of the tissue surface, a step of measuring the temperatures of the active elements of the receiving chain of the radiometer, a step of measuring the currents consumed by the active elements of the receiving chain of the radiometer, a step of measuring the power of the radio noise signal originating from the tissue, and a step of determining the blood glucose concentration based on the aforementioned values. The invention also relates to a computer program, a radiometer, and a device for determining glucose concentration.
Absstract of: USRE50976E
A wearable diagnostic device worn on a user's body that can provide various types of health-related information to the user is described. The wearable diagnostic device can provide real-time, non-invasive, accurate, and continuous data regarding a user's heart rate, hemoglobin level, body temperature, oxygen level, glucose level, and blood pressure. In some implementations, the wearable diagnostic device may also provide electrocardiogram (EKG) data or detection of Parkinson's symptoms, such as the involuntary movement of a user's hand. A user may configure the wearable diagnostic device to provide information on one, multiple, or all of the health-related information noted above.
Absstract of: NZ800857A
Described herein are fixed doses and dosing regimens for long-acting insulin receptor agonists suitable for once-weekly dosing, such as weekly basal insulin-Fc (BIF).
Absstract of: US20260215686A1
0000 Various embodiments of systems, devices and methods for improving the accuracy of an analyte sensor and for detecting sensor fault conditions are disclosed. According to some embodiments, these systems, devices, and methods can utilize a first data collected by a glucose sensor and a second data collected by a secondary sensing element. In some embodiments, the secondary sensing element can be one of a lactate sensing element, a ketone sensing element, or a heart rate monitor, among others.
Absstract of: US20260216060A1
0000 The present disclosure provides a matrix microneedle patch made of a hyaluronic acid (HA) polymeric backbone functionalized with needle height dopamine (DA) and 4-amino-3-fluorophenylboronic acid (AFBA, pKa~7.5) that quickly and spontaneously crosslinks upon mixing of the polymer solutions by auto-oxidation of catechol groups and reversible interactions between AFBA and catechol functional groups in the absence of any chemical crosslinking agent. The DA and AFBA content were selected for conjugation into the backbone of the HA polymer for the desired hormone delivery profile. The patch provides high drug loading capacity for long-term drug delivery application. The crosslinking mechanism for microneedle fabrication is biocompatible and beneficial for sustaining hormone drug stability and bioactivity as it does not require harsh crosslinking conditions. Facile pH adjustment of the matrix hydrogel can be easily casted into a microneedle patch without multistep processes that conventional patch polymerization requires. The present matrix microneedle patch demonstrates sufficient skin penetration, rapid swelling in interstitial media, high drug loading capacity and effective hypo/hyperglycemia prevention by the automated hypo/hyperglycemia-triggered delivery of hormones through the skin.
Absstract of: US20260216283A1
0000 Chronic wounds are characterized by a persistent, hyper-inflammatory environment that prevents progression to regenerative wound closure. Such chronic wounds are especially common in diabetic patients, often requiring distal limb amputation, but occur in non-diabetic, elderly patients as well. Induced expression of HoxA3, a member of the Homeobox family of body patterning and master regulatory transcription factors, has been shown to accelerate wound closure in diabetic mice when applied topically as a plasmid encased in a hydrogel. We now provide independent replication of those foundational in vivo diabetic wound closure studies and expand upon them with minimal dose threshold estimation. Furthermore, we observed similarities in natural wound healing velocity between aged non-diabetic mice and young diabetic mice, which provided motivation to test topical HoxA3 plasmid in aged non-diabetic mice, where we again observed accelerated wound healing. We did not observe any gross adverse effects macroscopically or via local histology in these short studies. Whether as a plasmid or future alternative modality, topical HoxA3 is an attractive translational candidate for chronic wounds.
Absstract of: US20260215703A1
0000 Provided is a sensor applicator assembly for a blood glucose monitoring, comprising an applicator, and a body attachment unit disposed inside the applicator and comprising a housing including an upper frame and a lower frame. The lower frame comprises a recess portion formed throughout an entire section along a perimeter direction.
Absstract of: US20260219259A1
A method to rapidly and inexpensively quantify human insulin secreted from human cells. This method for quantifying insulin secretion capacity in a human cell involves culturing a recombinant cell and measuring an amount of a secreted fused C-peptide. The recombinant cell is prepared by replacing an insulin gene in the genome of a human cultured cell line with a gene which expresses a fused C-peptide having a detectable tag peptide inserted in a C-peptide chain in a human proinsulin molecule.
Absstract of: WO2026157245A1
Disclosed in the present application are a method for evaluating blood glucose, a user interface, and a related apparatus. The method comprises: obtaining a PPG signal of a user in a time period; displaying the acquisition progress of the PPG signal in the process of obtaining the PPG signal; and then determining a blood glucose result of the user on the basis of the PPG signal, and displaying the blood glucose result. When the acquisition progress of the PPG signal is determined, the method can divide the PPG signal into PPG signal intervals in a plurality of windows by using a specified duration as a window size, and determine a ratio of the number of valid PPG signal intervals in the plurality of PPG signal intervals to a preset number as the acquisition progress of the PPG signal. It can be seen that the method determines the acquisition progress of the PPG signal according to the number of valid PPG signal intervals divided from the PPG signal, such that the acquisition progress of the PPG signal better aligns with the user's actual perception of the signal acquisition progress during the course of PPG signal acquisition.
Absstract of: US20260215704A1
A medical device includes a medical tool such as an inserter for a continuous glucose monitor. Typically a housing of the medical tool has an indicator area with an indicator field that irreversibly changes its appearance at a predetermined environmental parameter condition. In exemplary embodiments, the predetermined environmental parameter condition can be a predetermined humidity, a change in a predetermined humidity condition, a predetermined temperature or a predetermined temperature change. A controller is connected to the medical tool and is configured to determine the appearance of the indicator field at the time of use of the medical tool and is also configured to control the function of the medical tool based upon the determined appearance of the indicator field.
Absstract of: US20260215741A1
Methods, devices, systems, and kits are provided that buffer the time spaced glucose signals in a memory, and when a request for real time glucose level information is detected, transmit the buffered glucose signals and real time monitored glucose level information to a remotely located device, process a subset of the received glucose signals to identify a predetermined number of consecutive glucose data points indicating an adverse condition such as an impending hypoglycemic condition, confirm the adverse condition based on comparison of the predetermined number of consecutive glucose data points to a stored glucose data profile associated with the adverse condition, where confirming the adverse condition includes generating a notification signal when the impending hypoglycemic condition is confirmed, and activate a radio frequency (RF) communication module to wirelessly transmit the generated notification signal to the remotely located device only when the notification signal is generated.
Nº publicación: WO2026156536A1 30/07/2026
Applicant:
BRAIN EVEREST SHENZHEN TECH CO LLC [CN]
\u8111\u73E0\u5CF0\uFF08\u6DF1\u5733\uFF09\u79D1\u6280\u6709\u9650\u8D23\u4EFB\u516C\u53F8
Absstract of: WO2026156536A1
The present application discloses a video product for inducing a cognitive impairment behavior, and a storage medium. The video product comprises a plurality of video units, each video unit comprises a plurality of video clips, and each video clip displays a target element, a prompt element and/or an interference element. In the present application, by means of different elements in the video clips, a subject is induced to make behavioral responses, thereby measuring multiple types of cognitive abilities of the subject including visuospatial ability, memory ability, language ability, calculation ability, complex attention ability, smooth pursuit ability, execution ability, social cognition ability, emotional response ability, incongruity detection ability, and narrow vision ability, thus achieving screening, diagnosis, treatment, and efficacy evaluation of cognitive impairment caused by Alzheimer's disease, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, diabetes, and the like. By using the video product of the present invention, the processes of the described screening, diagnosis, treatment, and efficacy evaluation are more objective, and the results have higher reliability and consistency.
BOPI
Electronic site
